
Maurizio O Cosimelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4053237/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Prospective Study Evaluating Health-Related Quality of Life Following a Multimodal Treatment for Colorectal Cancer. Journal of Gastrointestinal Cancer, 2023, 54, 117-125.	0.6	3
2	Low baseline neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict increased overall survival in locally recurrent rectal cancer despite R1 margins. Digestive and Liver Disease, 2022, , .	0.4	2
3	Prediction of R0/R+ surgery by different classifications for locally recurrent rectal cancer. Updates in Surgery, 2021, 73, 539-545.	0.9	4
4	No benefit after neoadjuvant chemoradiation in stage IV rectal cancer: A propensity score-matched analysis on a real-world population. Digestive and Liver Disease, 2021, 53, 1041-1047.	0.4	3
5	Organâ€saving surgery for rectal cancer after neoadjuvant chemoradiation: Analysis of failures and longâ€term results. Journal of Surgical Oncology, 2020, 121, 375-381.	0.8	2
6	Neoadjuvant (re)chemoradiation for locally recurrent rectal cancer: Impact of anatomical site of pelvic recurrence on long-term results. Surgical Oncology, 2020, 35, 89-96.	0.8	10
7	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. ESMO Open, 2020, 5, e001001.	2.0	11
8	A proposal of an updated classification for pelvic relapses of rectal cancer to guide surgical decisionâ€making. Journal of Surgical Oncology, 2020, 122, 350-359.	0.8	13
9	Elective colorectal cancer surgery at the oncologic hub of Lombardy inside a pandemic COVIDâ€19 area. Journal of Surgical Oncology, 2020, 122, 117-119.	0.8	10
10	Tumor Regression Grade After Neoadjuvant Chemoradiation and Surgery for Low Rectal Cancer Evaluated by Multiple Correspondence Analysis: Ten Years as Minimum Follow-up. Clinical Colorectal Cancer, 2018, 17, e13-e19.	1.0	26
11	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). ESMO Open, 2017, 2, e000147.	2.0	36
12	Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 135.	3.5	9
13	Detection of Phosphorylated Insulin Receptor in Colorectal Adenoma and Adenocarcinoma: Implications for Prognosis and Clinical Outcome. Journal of Cellular Physiology, 2015, 230, 562-567.	2.0	18
14	Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity after radioembolization with yttrium-90 resin microspheres. Journal of Experimental and Clinical Cancer Research, 2013, 32, 13.	3.5	16
15	Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S11-S16.	1.5	7
16	The evolution of radioembolisation. Lancet Oncology, The, 2012, 13, 965-966.	5.1	3
17	High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. Journal of Translational Medicine, 2011, 9, 184.	1.8	55
18	Evaluation of a screening programme for psychological distress in cancer survivors. Supportive Care in Cancer, 2010, 18, 1545-1552.	1.0	11

#	Article	IF	CITATIONS
19	Liposarcoma of the colon presenting as an endoluminal mass. World Journal of Surgical Oncology, 2009, 7, 78.	0.8	29
20	Sexual dysfunction following surgery for rectal cancer - a clinical and neurophysiological study. Journal of Experimental and Clinical Cancer Research, 2009, 28, 128.	3.5	27
21	Randomized, Multicenter, Phase IIB Study of Preoperative Chemoradiotherapy in T3 Mid-Distal Rectal Cancer: Raltitrexed + Oxaliplatin + Radiotherapy Versus Cisplatin + 5-Fluorouracil + Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 403-412.	0.4	37
22	Survival of hereditary non-polyposis colorectal cancer patients compared with sporadic colorectal cancer patients. Journal of Experimental and Clinical Cancer Research, 2008, 27, 39.	3.5	37
23	Sphincter Preservation in Four Consecutive Phase II Studies of Preoperative Chemoradiation: Analysis of 247 T3 Rectal Cancer Patients. Tumori, 2007, 93, 160-169.	0.6	13
24	HLA-A, -B, -C Expression in Colon Carcinoma Mimics That of the Normal Colonic Mucosa and is Prognostically Relevant. American Journal of Surgical Pathology, 2007, 31, 76-84.	2.1	22
25	Long-Term Results After Neoadjuvant Radiochemotherapy for Locally Advanced Resectable Extraperitoneal Rectal Cancer. Diseases of the Colon and Rectum, 2006, 49, 311-318.	0.7	43
26	Cell surface overexpression of galectin-3 and the presence of its ligand 90k in the blood plasma as determinants in colon neoplastic lesions. Glycobiology, 2004, 14, 783-792.	1.3	32
27	Prognostic value of soluble P-selectin levels in colorectal cancer. International Journal of Cancer, 2004, 111, 404-408.	2.3	37
28	Association between Serum Carcinoembryonic Antigen and Endothelial Cell Adhesion Molecules in Colorectal Cancer. Oncology, 2003, 65, 132-138.	0.9	16
29	Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. International Journal of Radiation Oncology Biology Physics, 2002, 53, 664-674.	0.4	303
30	c-Myb and Bcl-x Overexpression Predicts Poor Prognosis in Colorectal Cancer. American Journal of Pathology, 2001, 158, 1289-1299.	1.9	122
31	Preoperative Chemoradiation and Total Mesorectal Excision Surgery for Low T ₃ Rectal Cancer. Tumori, 2001, 87, 31-33.	0.6	2
32	Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies. International Journal of Radiation Oncology Biology Physics, 2001, 51, 371-383.	0.4	116
33	p53 Nuclear Accumulation and Multiploidy Are Adverse Prognostic Factors in Surgically Resected Stage II Colorectal Cancers Independent of Fluorouracil-Based Adjuvant Therapy. American Journal of Clinical Pathology, 2001, 116, 360-368.	0.4	25
34	Treatment of peritoneal carcinomatosis with intent to cure. Journal of Surgical Oncology, 2000, 74, 41-44.	0.8	76
35	Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation. International Journal of Radiation Oncology Biology Physics, 1999, 45, 1175-1184.	0.4	69
36	Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl-2. , 1999, 84, 545-552.		85

MAURIZIO O COSIMELLI

#	Article	IF	CITATIONS
37	Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: Lack of correlation. , 1997, 72, 949-954.		52
38	Coloanal anastomosis for rectal cancer. Diseases of the Colon and Rectum, 1995, 38, 807-812.	0.7	105
39	CA 72-4 Serum Marker–A New Tool in the Management of Carcinoma Patients. Cancer Investigation, 1995, 13, 227-238.	0.6	45
40	Improved local control and survival with the "sandwich―technique of pelvic radiotherapy for resectable rectal cancer. Diseases of the Colon and Rectum, 1994, 37, S6-S15.	0.7	0
41	Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, part I. Diseases of the Colon and Rectum, 1994, 37, S16-S23.	0.7	7
42	Biologic and clinical correlations among ploidy, cell kinetics, and the tumor-associated glycoprotein-72 tissue expression in colorectal cancer. Diseases of the Colon and Rectum, 1994, 37, S24-S29.	0.7	4
43	Concomitant preoperative radiochemotherapy in operable locally advanced rectal cancer. Diseases of the Colon and Rectum, 1994, 37, S69-S72.	0.7	26
44	TAC-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. Cancer, 1993, 72, 2098-2106.	2.0	51
45	Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A lingitudinal study. Cancer, 1991, 68, 2443-2450.	2.0	36
46	Clinical evaluation of serum tumor-associated glycoprotein-72 as a novel tumor marker for colorectal cancer patients. Journal of Surgical Oncology, 1991, 48, 16-20.	0.8	8
47	Radical surgery in rectal cancer patients: What does it mean today?. Journal of Surgical Oncology, 1991, 48, 24-31.	0.8	9
48	Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and I.V. 5-fluorouracil (5-FU) chemotherapy for unresectable colorectal liver metastases: An alternative to FUdR-based regimens?. Journal of Surgical Oncology, 1991, 48, 63-68.	0.8	6
49	Local recurrence after curative resection for colorectal cancer: Frequency, risk factors and treatment. Journal of Surgical Oncology, 1991, 48, 155-160.	0.8	64
50	Multivariate analysis of a tissue CEA, TPA, and CA 19.9 quantitative study in colorectal cancer patients. Diseases of the Colon and Rectum, 1989, 32, 389-397.	0.7	23